Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
5 hedge funds and large institutions have $422K invested in Reviva Pharmaceuticals Warrants in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
17% less funds holding
Funds holding: 6 → 5 (-1)
57% less capital invested
Capital invested by funds: $979K → $422K (-$557K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$70K |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$9.78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
1
BlueCrest Capital Management
St Helier,
Jersey
| $333K | – | – | – |
|
|
AA
2
AQR Arbitrage
Greenwich,
Connecticut
| $26K | -$9.78K | -37,472 | -27% |
|
3
Walleye Capital
New York
| $24K | – | – | – |
|
|
AI
4
Arena Investors
Purchase,
New York
| $21K | – | – | – |
|
5
Walleye Trading
New York
| $18K | – | – | – |
|
|
6CM
6
683 Capital Management
New York
| – | -$70K | -200,000 | Closed |
|
RVPHW Hedge Fund Activity: Q1 2022 in Review
5 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q1 2022, worth a combined $422K — down 57% from $979K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RVPHW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was 683 Capital Management, exiting entirely with an estimated $70K sold.
- 5 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q1 2022, down from 6 in Q4 2021.
- Funds reported $422K of Reviva Pharmaceuticals Warrants stock for Q1 2022, down 57% quarter-over-quarter.
- 0 funds opened new Reviva Pharmaceuticals Warrants positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest Reviva Pharmaceuticals Warrants seller in Q1 2022 was 683 Capital Management, an estimated $70K sold.
Based on aggregated 13F filings for Q1 2022.